CME/CE

PIK3CA-related overgrowth spectrum (PROS) refers to various clinical entities that share the same pathogenetic mechanism. These disorders are caused by somatic gain-of-function PIK3CA mutations. Diagnosis of PROS is often challenging and requires DNA sequencing of the affected tissue. PIK3CA genetic mutations vary greatly depending on the tissue being tested. PROS is not considered an inherited disease.

The road to a diagnosis of a rare disease can be a long, winding process. Because of its rarity, a wide spectrum of symptoms, and disease heterogeneity, patients may feel alone and as though they are the only ones with the disease. Management of PROS currently involves symptomatic treatment of its manifestations; an unmet need exists for targeted, systemic therapies.

Currently, there is no cure for PROS. This educational activity will assist the interprofessional care team to better understand, apply, and interpret advances in current and emerging evidence that will help bridge the gap toward faster adoption into patient care.

HER2-Directed ADCs in Breast Cancer

Join us to discover optimal ways to identify women at risk or with atherosclerotic cardiovascular disease (ASCVD). In this Women’s Health 2021 lecture, our experts, Dr. Gregory Pokrywka and Dr. Karol Watson, dive deeper into evidence-based approaches to assess and manage ASCVD in women. They discuss topics from lifestyle modifications to recent clinical trial data on the use of omega-3 fatty acids for ASCVD event reduction.

Please note: This activity is no longer available for continuing education credit.

There is a lack of available therapeutic options for the management of patients with myeloid malignancies, including myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML). Novel therapeutic approaches are being evaluated, particularly those that target the NEDD8-activating enzyme (NAE). Evaluating the rationale for NAE inhibition, assessing emerging safety and efficacy data on use of NAE inhibitors in myeloid malignancies, and developing strategies based on the evolving implications of this research will allow for greater understanding of their potential impact on management and health outcomes of patients with MDS, CMML, and AML.

This Expert Exchange webcast aims to improve clinicians’ awareness of emerging agents in the treatment of patients with ADPKD.

This Expert Exchange webcast aims to improve clinicians’ ability to manage patients diagnosed with ADPKD.

This Expert Exchange webcast aims to improve clinicians’ ability to properly monitor disease progression and make treatment decisions based on prognostic indicators.

This Expert Exchange webcast aims to improve clinicians’ ability to detect and diagnose ADPKD in at-risk patients.

This Expert Exchange webcast aims to better define the importance radiological imaging plays in the management of patients with autosomal dominant polycystic kidney disease (ADPKD).

Please note: This activity is no longer available for continuing education credit.

This Expert Exchange activity is designed to make clinicians aware of the potential for emerging pharmacotherapies in treating patients with Parkinson’s disease.

You can access the Clinical Compendium for Novel Therapies to Manage OFF Episodes in Patients with Parkinson’s Disease by clicking the link here.